Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%

Potential Treatment for Patients with Facial Erythema (Redness) Associated with Rosacea Allergan Expects PDUFA Date in First Half 2017 DUBLIN, May 24, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN) today announced that the New ... Biopharmaceuticals, Dermatology, FDAAllergan, Oxymetazoline, rosacea
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news